Retinoic acid (RA) inhibits tumor promotion in many models in vivo and in vitro, among them mouse epidermal JB6 cells. RA treatment suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA) induced AP-1 activity, an activity that is required for transformation of JB6 P+ cells. The molecular mechanism of AP-1 transrepression by retinoids is unclear, especially as related to inhibition of transformation. Overexpression of AP-1 components did not rescue TPA induced AP-1 activation nor did a GST pull down experiment implicate direct binding, thus rendering unlikely both a Jun/Fos-RA-RAR direct interaction and a Jun/Fos sequestration mechanism. Overexpression of p300, SRC-1 or pCAF did not abrogate AP-1 suppression by RA, thus arguing against coactivator competition. Overexpression of the corepressor silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) suppressed AP-1 activity. However, SMRT but not RA inhibited cJun transactivation, suggesting SMRT does not mediate RA transrepression. RA treatment also did not block TPA induced ERK phosphorylation, Jun/Fos family protein expression except for cFos, or DNA binding of the AP-1 complex. The transcriptional activities of full-length JunB and full-length Fra-1, but not the transactivation domain fusions, were increased by TPA treatment and suppressed by RA. Since these full-length fusions have bzip domains, the results suggest that JunB and/or Fra-1-containing dimers may constitute one target of RA for transrepression of AP-1.
Introduction
Carcinogenesis is a multistep process consisting of initiation, promotion and progression (Fearon and Vogelstein, 1990; Klein, 1981) . Regulators of responsible signaling pathways for each stage are potential targets for cancer prevention (Boutwell, 1989; Colburn et al., 1979 Colburn et al., , 1982 . A causal relationship between tumor promoter-induced neoplastic transformation and activation of transcription factor AP-1 has been demonstrated in mouse and human cell progression models (Bernstein and Colburn, 1989; Dong et al., 1994; Li et al., 1998) and in a dominant negative c-jun transgenic mouse (Young et al., 1999) . In the JB6 mouse epidermal cell clonal variants, AP-1 transactivation is induced by 12-Otetradecanoylphorbol-13-acetate (TPA) in transformation sensitive but not in resistant cells (Bernstein and Colburn, 1989) . TPA induced cell transformation is blocked by AP-1 inhibitors such as retinoids, glucocorticoids, and the dominant negative cJun (TAM67) (Dong et al., 1994; Li et al., 1996 Li et al., , 1997 . Retinoic acid (RA) is eective in inhibiting papilloma formation in mouse skin and transformation of mouse epidermal JB6 cells (Colburn et al., 1981; Li et al., 1996; Verma and Boutwell, 1977) . RA induces dierentiation of keratinocytes and suppresses tumor phenotype in several models (Bollag and Holdener, 1992; Fuchs and Green, 1980) . RA can also cause a reversible phenotypic suppression of the TPA-transformed JB6 cell line RT101 (Dong et al., 1995) .
The biological eects of RA are mediated by its receptors (RARs) in the nucleus. The RARs belong to a large superfamily of ligand-inducible transcription factors that include vitamin D and thyroid hormone receptors. The retinoid receptors consist of two subunits, RARs (a, b, g ) and RXRs (a, b, g) (Chambon, 1996) . It has been well documented that liganded nuclear receptors including RAR inhibit AP-1 activation (Fisher and Voorhees, 1996; Li et al., 1996 Li et al., , 1997 Pfahl, 1993; Resche-Rigon and Gronemeyer, 1998; Saatcioglu et al., 1994; . Transactivation of target genes through the RARE sequence is functionally dissociated from transrepression of AP-1 (Bollag and Holdener, 1992; Fanjul et al., 1994; Fuchs and Green, 1980; Li et al., 1996) . Inhibition of tumor promotion by RA appears to be mediated by blocking AP-1 activation, not by activating retinoic acid response element (RARE)-dependent transcription (Li et al., 1996) . Mouse JB6 cells express only RAR g and a, not RAR b, and the tumor promotion inhibiting activity has been attributed to the RAR g (Rudd et al., 1993) . RAR g is functionally predominant for transrepression in keratinocytes (Goyette et al., 2000) . The precise mechanism of transrepression of AP-1 by RA is not clear. Three mechanisms have been suggested. The ®rst is direct interaction between Jun or Fos proteins and liganded RAR (Pfahl, 1993) . The second is competition between liganded RAR and Jun or Fos proteins to bind transcriptional coactivators (Kamei et al., 1996; Lee et al., 1998) . The third is inhibition of cJun Nterminal kinase (JNK) (Caelles et al., 1997; Lee et al., 1999) .
The silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) was identi®ed as a corepressor which interacts with unliganded RAR. The interaction between SMRT and RAR is destabilized by ligand (Chen and Evans, 1995) . SMRT mediates the repressive eect of unliganded nuclear receptors through the recruitment of histone deacetylase complexes (Nagy et al., 1997) . SMRT also suppresses other transcription factors (e.g. AP-1 SRF, NFkB, and Oct-1) (Kakizawa et al., 2000; Lee et al., 2000) . Therefore, there is the possibility that RA treatment recruits SMRT from RAR to AP-1 complexes.
The results presented here render unlikely the previously suggested mechanisms as well as recruitment of corepressor SMRT. Instead, RA appears to target JunB and/or Fra-1-containing dimers.
Results

RA transrepresses TPA induced AP-1 activation
The concentrations of RA that inhibit TPA induced transformation of JB6 cells (Dong et al., 1994) , also inhibit TPA induced AP-1 activation (Figure 1 ). Dose dependent suppression by RA was observed at concentrations lower than 10 76 M, with higher concentrations showing no greater suppression.
No rescue of AP-1 activity from transrepression by jun or fos overexpression
If RAR inhibits AP-1 by direct interaction with Jun or Fos proteins to sequester them, overexpression of the sequestered AP-1 component should cancel the inhibition. A luciferase assay of AP-1 activation in cells cotransfected with Jun or Fos expression constructs was performed. Overexpression of JunD or JunB raised the basal level and prevented further induction of AP-1 by TPA. Expression of cFos substantially increased basal AP-1 activity and TPA treatment produced a further increase. Overexpression of cJun, Fra-1, Fra-2 or cFos enhanced both basal and TPA induced levels of AP-1 but failed to abrogate AP-1 transrepression by RA (Figure 2 ). When cJun, Fra-1, Fra-2, or cFos was expressed, the AP-1 activation level with TPA+RA was similar to the solvent control level. Furthermore, a GST pull down assay using GST-retinoic acid receptor g (the functionally predominant RAR in JB6 cells) did not detect ligand dependent interaction with AP-1 components of a JB6 nuclear extract, while RXR a was pulled down ligand independently as expected (data not shown). These results suggest that direct interaction of liganded RAR with Jun or Fos proteins is unlikely to contribute to AP-1 transrepression.
Concentration of coactivator is not limiting for transrepression
It has been suggested that the amount of available p300/CBP or SRC-1 can be limiting when AP-1 and RAR compete for binding to the coactivator (Kamei et al., 1996; Lee et al., 1998) . We asked whether any of these coactivators is limiting for AP-1 activity in RA treated cells. Overexpression of coactivator p300 or SRC-1 increased both basal and TPA induced AP-1 activity. However, neither of them reversed transrepression by RA (Figure 3) , nor did expression of ASC-2 (not shown) reverse transrepression.
Overexpression of pCAF ( Figure 3 ) inhibited AP-1 activation, suggesting pCAF is not involved in the coactivator complex of AP-1 in this context. To determine whether transrepression between RAR and AP-1 is mutual, endogenous RAR activity was RA. RA treatment transrepressed AP-1 activity while TPA treatment enhanced RARE activation, consistent with a report published elsewhere (Fukasawa et al., 2000) . In contrast to other reports (Kamei et al., 1996; Yang-Yen et al., 1991) , the transrepression between AP-1 and RAR is not mutual in JB6 cells (Figure 4) . Taken together the results suggest that coactivators p300, SRC-1 and pCAF are not limiting for AP-1 activation when it is transrepressed by RA in JB6 cells.
SMRT suppresses AP-1 activity differently from RA Liganding of RAR decreases its anity to corepressors (Chen and Evans, 1995) . Released corepressors may be recruited to the AP-1 complex resulting in suppression of transcriptional activity. Overexpression of corepressor SMRT suppressed both basal and TPA induced AP-1 activity ( Figure 5a ). We measured transcriptional activation of full-length cJun using a Gal4 transactivation assay. TPA treatment activated the Gal4 DNA binding domain (dbd)-cJun fusion construct. At a concentration that substantially inhibits AP-1 luciferase activation, RA treatment did not signi®cantly aect the TPA induced activation of GAL4dbd-cJun whereas SMRT expression suppressed cJun activation almost completely ( Figure 5b ). Similar results were seen with Gal4dbd-JunB or Gal4dbd-JunD. Thus SMRT appears to interact with Jun proteins or with the kinases that activate them. SMRT-mediated suppression of cJun, JunB or JunD activation can explain transrepression of AP-1 by SMRT, but it cannot explain transrepression of AP-1 by RA. Histone deacetylase (HDAC) is a calatytic subunit of a corepressor complex (Ayer, 1999) . A speci®c inhibitor of HDAC, trichostatin A (TSA), increased AP-1 activity in a dose dependent manner. HDAC thus appears to regulate AP-1 activity. However, TSA treatment did not rescue AP-1 activity from transrepression ( Figure 5C ). The RA+TPA value is about 40% of the TPA-only value at all TSA concentrations and without TSA. These results suggest Figure 3 Overexpression of coactivator did not rescue AP-1 activity. An expression construct of p300, SRC-1, or p/CAF or control DNA was transfected into JB6 cells. Then cells were treated with DMSO or TPA+RA. Triplicate samples were analysed for each condition. All experiments were performed in triplicate, and standard error of the mean is indicated. Three independent experiments showed similar results
Figure 2
Overexpression of Jun or Fos proteins did not rescue AP-1 activity. Each AP-1 component or pcDNA3.1 as a control DNA was cotransfected with AP-1 reporter construct. JB6 P (+) cells were exposed to 0.1% DMSO or TPA+RA for 18 h. Triplicate samples were run for each condition. All experiments were performed in triplicate, and standard error of the mean is indicated. Three independent experiments showed similar results. Note the dierent scales for the right and left groups that recruitment of corepressors SMRT or HDAC is not likely to be involved in transrepression of AP-1 by RA.
RA does not inhibit TPA induced ERK activation
Unidirectional transrepression between RAR and AP-1 (Figure 4 ) suggests that RA treatment blocks the TPA signaling pathway leading to AP-1 activation. Activation of MAP kinase ERKs 1 and 2 is required for TPA induced AP-1 activation and transformation of JB6 cells Watts et al., 1998) . TPA treatment rapidly increased the amount of phospho-ERK1/2, an activated form of ERKs. Peak activation was observed at 30 min followed by a gradual decrease. Simultaneous RA treatment did not inhibit TPA induced ERK activation nor did it accelerate subsequent inactivation ( Figure 6 ). The data suggest that RA does not block the TPA signaling pathway at the stage of ERK activation or events upstream of ERK required for the activation of ERK.
RA does not inhibit TPA induced synthesis of most Jun or Fos proteins or inhibit DNA binding of the AP-1 complex TPA treatment induces c-Jun, JunB, c-Fos, and Fra-1 expression within 4 hours (Bernstein et al., 1992; Bernstein and Walker, 1999) . However, simultaneous treatment with RA did not inhibit TPA induced Jun family, Fra-1, or Fra-2 expression (Figure 7a ). Some decrease in cFos expression was seen at 3 and 6 h following TPA+RA treatment. However, the lack of AP-1 rescue (Figure 2 ) by cFos expression, suggests that the RA reduced level of cFos is not limiting for AP-1 activation. RA treatment did not block TPA induced DNA binding of the AP-1 complex ( Figure  7b ). Thus, RA inhibition of TPA induced Jun/Fos protein expression does not appear to explain RA transrepression of AP-1, nor does RA inhibit the formation of AP-1 complexes on DNA.
RA targets the transcriptional activation of full-length JunB and Fral
Activation of AP-1 components is the last step to AP-1 regulated transcription and might be a target of transrepression. We measured transcriptional activation of the transactivation domain located at the Nterminus of cJun, JunB, or JunD using a Gal4 transactivation assay (TA). None of the JunTA proteins was both activated by TPA and suppressed by RA. We then measured the transcriptional activity of full-length Jun genes. All of the Jun family proteins showed increased transcriptional activity with TPA treatment. RA speci®cally suppressed full-length JunB transactivation (Figure 8a ) albeit it a partial transrepression. To determine the contribution of Fos family genes to transrepression, we measured the transcriptional activation of all but Fos B, a protein that is absent from JB6 cells and from mouse epidermis (Angel et al., 2001; Bernstein and Walker, 1999) . At the serum concentration needed to observe AP-1 transrepression by RA, neither full-length cFos nor the C-terminal transactivation domain (CTA) was activated by TPA treatment. Both full-length and Cterminal Fra-1 were activated by TPA. Full-length but not C-terminal Fra-2 was activated by TPA. Among them, only full-length Fra-1 activation was signi®cantly suppressed by RA treatment. Contransfection of either a full-length JunB or a full-length Fra-1 Gal4 fusion with a cDNA expression construct of a heterodimer partner (i.e. cFos, Fra-1, or Fra-2, for JunB) showed similar results to those shown in Figure 8 (data not shown). That is, expression of cFos, Fra-1, or Fra-2 Competition between AP-1 and RAR to bind coactivators p300, SRC-1, or pCAF (iii) recruitment of corepressor SMRT or HDAC. An AP-1 complex consisting of JunB and Fra-1 or another JunB-or Fra-1-containing complex appears to be one target of transrepression by RA. A recent study using RAR null keratinocytes revealed that RAR is essential for the transrepression of AP-1 activity by RA (Goyette et al., 2000) . RARg plays a major role in AP-1 transrepression by RA in JB6 cells (Rudd et al., 1993) . Mutational analysis of RAR de®ned the DNA binding domain and the Cterminal transactivation domain (AF2) as crucial for transrepression of AP-1 (DiSepio et al., 1999) .
However, the details of the mechanism of AP-1 transrepression by RA have been uncertain. A crosslinking and coprecipitation approach suggested that RAR can physically associate with both c-Jun and cFos (Yang-Yen et al., 1991) . However, these proteinprotein interactions appear to be weak or indirect, since our data and other reports suggest that direct interaction between AP-1 and RAR is unlikely (Nicholson et al., 1990) . p300 and SRC-1 can act as coactivators for RAR or AP-1 mediated transcription (Kamei et al., 1996; Lee et al., 1998) . pCAF has been shown to be a coactivator of RAR (Blanco et al., 1998) . In this study, we showed that pCAF is not involved as a coactivator in AP-1 mediated transcription. Competition between AP-1 and RAR to bind p300 or SRC-1 appears not to explain transrepression in JB6 cells. Unidirectional transrepression also argues against the simple competition mechanism.
RA might repress AP-1 activity through inhibition of Jun N-terminal kinase (JNK) (Caelles et al., 1997; Lee et al., 1998 Lee et al., , 1999 . Transformation by TPA does not, however, require JNK in JB6 cells. Expression of dominant negative Jun kinase did not inhibit transformation by TPA while it did inhibit transformation by tumor necrosis factor alpha (Huang et al., 1999) . Since TPA induced transformation requires AP-1 but not JNK, it appears likely that JNK is not required for AP-1 activation. TPA treatment produced no detectable activation of JNK whereas TNFa did activate JNK (data not shown). The lack of signi®cant activation of the transactivation domain of Jun family Watts et al., 1998) . Fra-1 activation is one of the subsequent steps following ERK activation leading to activation of AP-1 dependent transcription (Young et al., 2001) . Our data (Figure 8b ) suggest these steps are not aected by RA treatment. Therefore, RA might target the interaction between the AP-1 complex and the basal transcriptional machinery. DNA binding studies using in vitro translated cJun suggested that RARs are able to antagonize AP-1 activity by interfering with DNA binding ability Yang-Yen et al., 1991) . Our data using a nuclear extract (Figure 3b ) suggest that RA treatment does not block the DNA binding activity of AP-1, a ®nding that is consistent with a report using glomerular mesangial cells (Simonson, 1994) . Except for cFos, TPA induced expression of Jun and Fos proteins was not inhibited by RA treatment. The fact that cFos expression failed to reverse RA transrepression suggests that the RA-reduced level of cFos is not limiting for AP-1 transactivation.
When fused to a heterologous DNA binding domain like Gal4, Jun or Fos proteins can activate transcription with their intrinsic activation domain (Sutherland et al., 1992) . The leucine zipper motif has no transactivation activity by itself but a fusion construct of Gal4dbd with a leucine zipper might recruit a dimer partner molecule resulting in activation of a reporter construct (Smith and Bohmann, 1992) . Speci®c inhibition of full-length JunB and full-length Fra1 transactivation by RA suggests three possible mechanisms. The ®rst is that RA inhibits a coactivator (or activates a corepressor) that regulates transactivation of a speci®c AP-1 dimer. The second is that RA inhibits the dimerization of Jun and Fos, a possibility that is suggested by Zhou et al., 1999) . The third possibility is that the full-length JunB or full-length Fra-1 binds to a non-AP-1 transcription factor protein through the bzip domain. Precedent for this is found in the binding of the NFkB p65 rel homology domain to the bzip domain of some but not all Jun or Fos proteins (Stein et al., 1993) . The inhibition of dimerization is unlikely in the present case because RA treatment did not block the DNA binding of AP-1, a process that requires dimerization. In conclusion, RA appears to target JunB-and/or Fra-1-containing dimers in which the binding partner binds to the bzip domain. The dimer may be an AP-1 heterodimer or it may be JunB or Fra-1 bound to a non-AP-1 transcription factor, and this may contribute at least in part to the transrepression of AP-1 by RA in JB6 cells.
Materials and methods
Reagents and cell culture
All trans retinoic acid was purchased from Sigma (St. Louis, MO, USA). TPA was from LKB Laboratories, Inc. (St. Paul, MN, USA). DMSO was from Pierce (Rockford, IL, USA). Antibodies against c-Jun (H-79), JunD (329), JunB (N-17), cFos (H-125), Fra-1 (N-17), Fra-2 (L-15) and FosB (102) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Trichostatin A (TSA) was from Wako chemicals USA (Richmond, VA, USA). Transformation sensitive JB6 mouse epidermal cell line (Cl 41) were grown at 368C in Eagles Figure 8 RA targets transactivation of full-length JunB and Fra1. (a) Gal4 transactivation assay of jun family genes. Cells were treated with DMSO or TPA+RA for 6 h after transfection. cJun, JunB, and JunD; Gal4dbd fused to full-length cJun, JunB and JunD, respectively. cJunTA, JunBTA, JunDTA; Gal4dbd fused to transactivation domain of cJun (amino acids (aa) 1 to 223), JunB (aa 1 to 203) and JunD (aa 1 to 151), respectively. The asterisk in 8A indicates statistical signi®cance at P50.01, for RA transrepression of FL JunB. (b) Gal4 transactivation assay of fos family genes. Cells were treated with DMSO or TPA+RA for 12 h after transfection. cFos, Fra1, and Fra2; Gal4dbd fused with full-length cFos, Fra1, and Fra2 gene, respectively. cFosCTA, Fra1C, and Fra2C; Gal4dbd fused with C-terminal transactivation domain of cFos (aa 208 ± 313), C-terminal part of Fra1 (aa 128 to 271), and C-terminal part of Fra2 (146 to 327), respectively. The asterisk in 8B indicates statistical signi®cance at P50.02 for transrepression of FL Fra-1. Each experiment had triplicate samples. Representative data of three independent experiments is shown. Bar indicates standard error for fold induction. The value for untreated sample was set at 1.0, thus showing no standard error Minimum Essential Media (EMEM) (BioWhitaker, Frederick, MD, USA) supplemented with 4% Fetal Bovine Serum (FBS), 2 mM L-Glutamine and 25 mg/ml Gentamicin (Life Technology/Gibco, Gaithersburg, MD, USA).
Plasmids
AP-1 Luciferase reporter plasmids consisting of Luciferase reporter gene driven by the promoter harboring the appropriate element were constructed as previously described (Dong et al., 1995 . The AP-1 reporter plasmid consists of Fire¯y Luciferase genes driven by an AP-1 responsive promoter containing four copies of¯anked AP-1 consensus sequence (TCGACTATGATGAGTCATGGGGC) from GCN4 and a minimal Albumin promoter region with TATA box (AAGCTTAGAATCTAGTATATTAGAGC-GAGTCTTTCTGCACACAGATCACCTTTCCTATCAAC-CCCACTACCATACCCTTCCTCCATCTATACCACCCT-ACTCTGC AGGTCGAC). Expression constructs were generated by inserting full-length cDNA of c-jun (human), junB, junD, c-fos, fra-1 or fra-2, and fosB (mouse) into the cloning site of eukaryotic expression vector pcDNA3 (Invitrogen, Carlsbad, CA, USA). Full length p300 expression vector controlled by the CMV promoter was kindly provided by Dr Lisa Felzien (Felzien et al., 1998) . SalI ± NotI fragment of full-length p300 cDNA was cloned into XhoI ± NotI site of pcDNA3.1(7) because original construct did not give p300 expression in JB6 cells. SRC-1 and p/CAF expression constructs were kindly provided by Dr Mitchell Lazar and Dr Yoshihiro Nakatani, respectively. RARg expression vector was provided by Dr Pierre Chambon. A full-length cDNA of the RARg gene was ampli®ed by PCR, digested with EcoRI/BamHI, and cloned into the pGEX-3X vector (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA) to make a GST-RARg fusion expression construct. pFR-luc, pFA-cfos for Gal4 transactivation assay were purchased from Stratagene (La Jolla, CA, USA). Expression constructs of Gal4 DNA binding domain (Gal4dbd) fused to full-length jun family gene (pMcjun, pMjunD, and pMjunB) were provided by Dr Sunita Agarwal (Agarwal et al., 1999) . Expression constructs of Gal4dbd fused with transactivation domain (amino acids (aa) 1 to 223) of c-jun (pFA-cJun) or Cterminal transactivation domain (aa 208 ± 313, pFA-cFos) was purchased from Stratagene. C-terminal part of fral (aa 128 to 271) or fra2 (146 to 327) with partial leucine zipper fused to Gal4dbd fusion constructs were described previously (Young et al., 2001 ). An expression construct of Gal4dbd fused with the transactivation domain (aa 1 to 151) of junD (pBindjunD) was provided by Dr Tim Bowden (Rosenberger et al., 1999 ). An expression construct of Gal4dbd fused with the transactivation domain of junB (aa 1 to 203) was made by excising SacI ± HindIII fragment of pMjunB. The RARELuciferase construct was described previously (Li et al., 1996) . Mouse full-length SMRT expression construct was kindly provided by Dr R Evans (Chen et al., 1996) . Full-length mouse cfos, fra-1, and fra-2 cDNA were ampli®ed by PCR with following sets of primers. cfos: 5'-ATGGATC-CATGATGTTCTCGGGTTTCAAC-3' and 5'-TAGAATTC-TCACAGGGCCAGCAGCGTGG-3' fra-1: 5'-ATGGATCC-CAGGGCATGTACCGAGAC-3' and 5'-TAGAATTCTCA-CAAAGCCAGGAGTGTAG-3' fra-2: 5'-ATGGATCCATG-TACCAGGATTATCCCGG-3' and 5'-TAGAATTCTTAC-AGGGCTAGAACTGTGG-3'. Ampli®ed cDNAs were digested with EcoRI and BamHI then cloned into EcoRI ± BamHI site of pFA expression vector (Stratagene) to make fusion constructs with the DNA binding domain of the Gal4 gene.
Nuclear protein extraction
JP6 P(+) cells were grown in 15 cm diameter dishes. Cells were treated with DMSO or TPA (10 ng/ml)+RA (10
77
) for 18 h. Cells were washed with PBS(7) once, then harvested with scraper and centrifuged. The collected cells were lysed with Lysis Buer containing 25 mM HEPES at pH 7.7, 50 mM KCl, 2 mM PMSF, 2 mg/ml Leupeptin, 4 mg/ml Aprotinin, 100 mM DTT and 0.5% NP-40. The resulting nuclei were washed with the above buer minus NP-40 (Washing Buer) and subsequently lysed with Extraction Buer containing 25 mM HEPES at pH 7.7, 500 mM KCl, 1 mM PMSF, 1 mg/ml Leupeptin, 2 mg/ml Aprotinin, 100 mM DTT and 10% Glycerol (or 8% Ficoll). All of the above procedures were performed at 48C and aliquots of nuclear extracts were stored at 7708C. Protein concentration was determined by Coomassie Blue Protein Assay Reagent from Pierce (Rockford, IL, USA). The supernatants were stored at 7708C as nuclear extracts.
EMSA (electrophoretic mobility shift assay)
Oligonucleotides containing AP-1 consensus sequence were purchased from Santa Cruz or synthesized by Gibco followed by annealing. Fifty nanograms of double stranded oligos were end-labeled using 32 P-g-ATP and T4 polynucleotide kinase (Roche Molecular Biochemicals, Indianapolis, IN, USA). The reaction mixture for EMSA consists of 50 000 c.p.m. of labeled and puri®ed oligonucleotides, 1 mg/ ml of poly (dI-dC) (Roche), and 1 ± 2 mg of nuclear extracts in binding buer containing 20 mM of Tris-HCl at pH 7.5, 50 mM KCl, 1 mM DTT, 2 mM EDTA and 4% Glycerol. The reaction was carried out at room temperature for 30 min. The protein-DNA complexes were resolved on a 6% TBE/ Gel Retardation gel (Invitrogen). The gel was dried and exposed to Kodak ®lm at 7708C overnight.
Preparation of whole cell lysate and Western blots
One610
5 cells/well of cells were seeded in six well plates. The next day, cells were treated with or without TPA+RA in EMEM with 0.2% FBS for appropriate time. Cells were washed with ice cold PBS once then lysed with lysis buer (2% SDS, 50 mM Tris-HCl pH 7.5). Western immunoblotting was carried out according to the ECL protocol from Amersham Pharmacia Biotech Inc. In brief, 10 mg of nuclear extracts or 20 ± 40 mg of whole cell lysates were boiled and denatured in Sample Buer containing SDS and DTT (Invitrogen) followed by gel electrophoresis using NuPage 10% Bis-Tris pre-packed gel (Invitrogen) in MOPS buer. Equal protein was loaded for each sample. The proteins were electro-transferred to nitrocellulose membrane (Schleicher and Schuell, Keene, NH, USA) using a semi-dry transfer blotting system from Enprotech Co. (Hyde Park, MA, USA). The resulting protein-bound membrane was blotted with selected antibodies and visualized using ECL reagents (Amersham Pharmacia). The cells for all samples were cultured and induced at the same time and the protein extracts were also prepared at the same time.
Luciferase assay for AP-1 dependent transactivation 
Gal4 transactivation assay
One610
4 cells were seeded in 24 well plates. The next day, 25 ng of pFR-luc (reporter construct with Gal4 binding site) and 50 ng of fusion construct of Gal4dbd and Jun or Fos gene were transfected using Fugene 6 (Roche). One day later, cells were treated with or without TPA+RA in 0.2% FBS with EMEM for 6 h. Luciferase activity was measured as described above. Each Fire¯y Luciferase activity driven by a speci®c promoter was normalized to its respective Renilla Luciferase activity driven by thymidine kinase promoter as a control for transfection eciency.
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